Travere Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Travere Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Travere Therapeutics Inc Strategy Report
- Understand Travere Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Travere Therapeutics Inc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
---|---|---|---|---|
08 Mar 2022 | Travere Therapeutics Raises USD316.25 Million in Public Offering of 2.25% Convertible Senior Notes Due 2029 | Debt Offering | - |
Travere Therapeutics Inc |
15 Sep 2021 | Vifor Pharma Enters into Licensing Agreement with Travere Therapeutics | Licensing Agreement |
Vifor (International) AG
|
Travere Therapeutics Inc |
10 Feb 2021 | Travere Therapeutics Raises USD201.4 Million in Public Offering of Shares | Equity Offering | - |
Travere Therapeutics Inc |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer